Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05450549 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants | PHASE1 | COMPLETED | 47 | — | — | Jul 14, 2022 | Jun 8, 2023 | Aug 16, 2023 | 1 | Netherlands |
| Arm | Type | Description |
|---|---|---|
| DNL919 (Healthy Participant) | EXPERIMENTAL | - |
| Placebo (Healthy Participant) | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| DNL919 | DRUG | Single doses |
| Placebo | DRUG | Single doses |
Key Inclusion Criteria: * Female participants of non-childbearing potential (surgically sterilized or post menopausal) or male participants, aged 18 to 55 years, inclusive * BMI 18.5 to \<30 kg/m² * When engaging in sex with a woman of child bearing potential, both the male participant and his fema...